.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Predict branded drug patent expiration
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
Express Scripts
Boehringer Ingelheim
Harvard Business School
AstraZeneca
Fuji
Healthtrust
Cerilliant
Argus Health

Generated: June 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 9,227,946

« Back to Dashboard

Claims for Patent: 9,227,946

Title:1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
Inventor(s): Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:14/242,337
Patent Claims: 1. A method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks, the method comprising administering a therapeutically effective amount of a hydrobromide salt of Compound I to a patient in need thereof, wherein Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine, the hydrobromide salt of Compound I is a crystalline compound characterized by XRPD reflections at 6.89, 9.73, 13.78 and 14.64+/-0.10.degree. 2.theta., and the method alleviates a symptom or complication of the disease or delays the progression of the disease.

2. The method of claim 1, wherein the hydrobromide salt is characterized by an XRPD as shown in FIG. 3.

3. The method of claim 1, wherein the hydrobromide salt has a particle size distribution corresponding to: D98%: 650-680 .mu.m; D50%: 230-250 .mu.m; and D5%: 40-60 .mu.m; D98%: 370-390 .mu.m; d50%: 100-120 .mu.m; and D5%: 5-15 .mu.m; D98%: 100-125 .mu.m; D50%: 15-25 .mu.m; and D5%: 1-3 .mu.m; or D98%: 50-70 .mu.m; D50%: 3-7 .mu.m; and D5%: 0.5-2 .mu.m.

4. The method of claim 1, wherein the disease is major depressive disorder.

5. The method of claim 1, wherein the disease is depression or major depressive disorder.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Express Scripts
UBS
Chubb
US Army
Moodys
Teva
US Department of Justice
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot